AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05757713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: teplizumab
Description: CD3-directed humanized monoclonal antibody
Study NCT04965142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The intervention group will be asked to complete aerobic exercises 3 to 5 times per week (≥ 150 minutes of at least moderate aerobic intensity) and resistance training at least twice a week over a 12-week period.
Study NCT04861129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bowen therapy
Description: Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
Study NCT04861129 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Bowen therapy
Description: Sham Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
Study NCT05177510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Progestin Antagonist
Study NCT05177510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04822675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valve repair
Description: Percutaneous mitral repair will be performed using the MitraClip system.
Study NCT04822675 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical mitral valve repair/replacement
Description: All mitral valve surgeries will be performed either via sternotomy or right thoracotomy, and with cardioplegic arrest and cardiopulmonary bypass. Mitral valve repair may include annuloplasty and adjunctive procedures as determined by the operating surgeon. For mitral valve replacement, the choice of mitral valve prosthesis will be left at the surgeon's discretion.
Study NCT06305156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Bone Mineral Density quantification
Description: In the first visit, participants receive clinically indicated CT scan, where bone mineral density will be derived.~In a second, study related visit, participants will receive a DXA scan for bone mineral quantifications.
Study NCT06071845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge Procedure
Description: Investigators will follow the Cytosponge Cell Collection Kit Instructions for Use to administer and retrieve the Cytosponge device.
Study NCT06071845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cytosponge Procedure
Description: Investigators will follow the Cytosponge Cell Collection Kit Instructions for Use to administer and retrieve the Cytosponge device.
Study NCT06071845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic Assessment
Description: Participants will undergo a diagnostic clinically indicated sedated endoscopy with standard endoscopic equipment.
Study NCT06071845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Assessment
Description: Participants will undergo a diagnostic clinically indicated sedated endoscopy with standard endoscopic equipment.
Study NCT05834439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flower printing activities for the elderly
Description: Experimental group
Study NCT05834439 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine activities in nursing home
Description: Control group
Study NCT05356234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Intervention: Responsible Parenting, Relationships, and Employment Services
Description: The Intervention group will be assigned a Case Manager and placed in the next available On My Shoulders (OMS) curriculum that offers strategies to help individuals develop a strong and healthy self in the service of making current and/or future relationships of all forms (parent-child, romantic, family, work) successful and satisfying. This curriculum is intended to equip men (and, where applicable, women) with the skills they need to build and nurture healthy relationships. This curriculum should help participants improve family functioning. Additionally, Transforming Impossible into Possible (TIP) financial literacy curriculum will be utilized to help participants increase job retention for those currently employed, improve wages through additional educational and training opportunities, and learn skills to better manage family finances. This curriculum should help participants increase economic stability and mobility.
Study NCT06196736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: 1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
Study NCT06196736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 75mg/m\^2 docetaxel by intravenous infusion or 175 mg/m\^2 paclitaxel by intravenous infusion on day 1 of every 21-day cycle.
Study NCT05506540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 1mg
Description: ENN0403 capsules for oral use
Study NCT05506540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 4mg
Description: ENN0403 capsules for oral use
Study NCT05506540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 10mg
Description: ENN0403 capsules for oral use
Study NCT05506540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 20mg
Description: ENN0403 capsules for oral use
Study NCT05506540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 30mg
Description: ENN0403 capsules for oral use
Study NCT05506540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 20mg (Fed)
Description: ENN0403 capsules for oral use
Study NCT05506540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 6mg QD X 14 Days
Description: ENN0403 capsules for oral use
Study NCT05506540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 12mg QD X 14 Days
Description: ENN0403 capsules for oral use
Study NCT05506540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 20mg QD X 14 Days
Description: ENN0403 capsules for oral use
Study NCT05506540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules for oral use
Study NCT04985526 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol)
Description: Administering Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) or 0,9% sodium chloride (as control agent) to the skin
Study NCT04985526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol)
Description: Administering Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) or 0,9% sodium chloride (as control agent) to the skin
Study NCT06032065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Treadmill Exercise
Description: This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
Study NCT06032065 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supervised Treadmill Exercise
Description: This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
Study NCT06032065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Exercise
Description: This is a 12 week intervention where participants will walk at home for exercise with guidance from a study coach. They will have 4 in person visits in the first four weeks and then have weekly phone calls in the last 8 weeks of the intervention with their coach.
Study NCT06032065 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Home-Based Exercise
Description: This is a 12 week intervention where participants will walk at home for exercise with guidance from a study coach. They will have 4 in person visits in the first four weeks and then have weekly phone calls in the last 8 weeks of the intervention with their coach.
Study NCT06032065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot Juice
Description: Participants will drink one shot of nitrate rich beet-root juice twice daily for 12 weeks.
Study NCT06131632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast conserving surgery
Description: Remove only a small part of the breast
Study NCT06131632 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical modified mastectomy
Description: Remove all the breast parenchyma, nipple and skin
Study NCT06301958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy
Description: A 25% dextrose solution is used to relieve arthritis of the knee joint like osteoarthritis and rheumatoid arthritis.
Study NCT05656339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CHO+WP
Description: Oral supplement containing carbohydrates plus whey protein
Study NCT05656339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CHO
Description: Oral supplement containing carbohydrates
Study NCT05656339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Fast
Description: Fast condition of 12 hours
Study NCT04658160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Longitudinal Tracking and Intervention Platform for Medicare Advantage Patients
Description: access to/use of the tracking platform
Study NCT04571749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized handoff
Description: A customized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
Study NCT06523296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adults with Alzheimer's disease
Description: Each patient will undergo a blood draw for the analysis of RACH antibodies in serum.~Also an aliquot of frozen spinal fluid of patient kept in biobank ( spinal fluid taken during a puncture as part of routine care) will be used for the analysis of RACH antibodies.
Study NCT06523296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adults with Myasthenia
Description: Each patient will undergo a blood draw for the analysis of RACH antibodies in serum.~Also an aliquot of frozen spinal fluid of patient kept in biobank ( spinal fluid taken during a puncture as part of routine care) will be used for the analysis of RACH antibodies.
Study NCT06523296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healhty controls
Description: Frozen spinal fluid of 10 healthy controlled stored in a biobank in Munster, Germanywill be compared to the ones of Adults with Myasthenia and Adults with Alzheimer's disease
Study NCT06223711 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiochemotherapy
Description: Radiotherapy to the primary tumor including mediastinal lymph node metastases is delivered in single fractions of 1.8Gy once daily up to a cumulative dose of 63.0Gy by intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT).
Study NCT06223711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab is administered in fixed dose 1500mg in q3w cycles concomitant to chemotherapy and q4w cycles during maintenance treatment
Study NCT06223711 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy of further tumor locations
Description: Stereotactic radiotherapy is delivered to the up to four further tumor locations during durvalumab maintenance therapy and will be performed according to local standards with established dose and fractionation schemes in ablative doses depending on the affected organ system.
Study NCT06223711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Concomitant chemotherapy consists of further two cycles platinum/etoposide q3w (summarized cycle 3-4).
Study NCT05532566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergenic extract
Description: In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
Study NCT04998071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride
Description: Analgesic efficiency comparison between two concentration of bupivacaine hydrochloride using for posterior quadratus lumborum block in LPEC
Study NCT04800965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient MyChart Scheduling Link
Description: Text message includes a link for patients to sign on to their patient portal (Epic MyChart) and schedule their COVID-19 vaccine appointment.
Study NCT04800965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Educational Video
Description: Text message includes a link to a patient education video that aims to encourage patients to obtain the COVID-19 vaccine.
Study NCT04800965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Follow through Message
Description: Text message includes information that will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
Study NCT04789252 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bioinformatics analysis of single cell transcriptomics data
Description: 1. Sample collection: Myeloid cell purification + Single cell sequencing~2. Primary analysis: QC sequencing data + Reads alignment + UMI quantification~3. Bioinformatics analysis: Quality Control (Number of genes, UMI content,%mitochondrial genes, % riboprotein genes,Filtering low quality cells) + Normalization and scaling (Normalization, Remove unwanted sources of variation, HVG detection) + PCA Clustering Markers (PCA and PC selection, Clustering, t-SNE, Differential expression for markers identification)~4. Validation: FACS analysis + immunohistochemistry
Study NCT05084040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 90 days interval between catheter maintenance
Description: Length of time between catheter maintenances extended from 60 days to 90 days
Study NCT05158270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Erector spinae plane block
Description: Patient will be placed in lateral decubitus position. By palpation of spinous processes starting from C7 downward, T7 spinous process will be located. Under complete aseptic precautions, linear probe of US machine will be placed in a transverse orientation at this level to identify tip of T7 transverse process (TP). By probe rotation into a longitudinal orientation, a parasagittal view will visualize skin and subcutaneous tissue, trapezius, and erector spinae (ES) muscle layers superficial to TPs. After local anesthetic (LA) infiltration, a 20 gauge spinal needle will be inserted in-plane and directed cranio-caudally until it contacts T7 TP. Target site for injection will be fascial plane deep to ES muscle. 1 mL saline will be injected to confirm correct needle-tip position by visualization of lifting of ES muscle off TP without distending the muscle and spreading cranio-caudally. 20 - 30 mL of 0.25% bupivacaine will be injected. Procedure will be performed bilaterally.
Study NCT05158270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Subcostal Anterior Quadratus Lumborum Block
Description: Patients will be positioned lateral decubitus. A curvilinear 2-5 MHz ultrasound transducer (SonoSite S-Nerve, Bothell, WA) will be positioned posteriorly below the 12th rib in a parasagittal oblique plane at L1-2 level. The QL muscle was visualized and its point of insertion on the 12th rib identified. An 18-gauge Tuohy needle was advanced in the caudal-to-cranial direction between QL muscle and the psoas major muscle until a click could often be felt as the needle tip penetrated the anterior investing fascia of the QL muscle. After a negative aspiration, 30 mL of 0.25% bupivacaine was injected through the needle to help confirm the final needle tip position, anterior to the QL muscle at close proximity to the 12th rib.
Study NCT05158270 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intravenous Multimodal Analgesia
Description: Postoperative pain in the post-anesthesia care unit (PACU) and on the ward will be treated with a combination of IV multimodal analgesia in the form of Acetaminophen (15 mg/kg 4/day) and Ketorolac (0.5 mg/kg 3/day) using a fixed scheme. In addition, Nalpuphine, as 3 mg IV bolus at each dose, will be given when Numerical Rating Scale (NRS) ≥ 3. VAS will be assessed 5 - 10 min. after each opioid dose to assess the need for additional opioid doses.
Study NCT05419583 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography
Description: CT scan of the heart arteries
Study NCT05419583 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography
Description: Invasive coronary angiography via the radial or femoral approach
Study NCT05939141 — intervention group
Intervention type: DEVICE
Intervention: Genio System
Description: All participants have previously been implanted with a Genio® system implantable stimulator. This research is observational in nature (long term safety follow-up) and participants will not be exposed to additional procedures.~The Genio System comprises of a bilateral Implantable Stimulator (IS), which is implanted via a minimally invasive surgery procedure and positioned over the genioglossus muscle with its electrodes positioned over both the left and right hypoglossal nerve branches. Stimulation of the hypoglossal nerve causes the tongue muscles to contract with the intention to maintain an open airway. The Implantable Stimulator receives energy pulses transmitted via the DP placed under the patient's chin and connected to the Activation Chip (AC), which contains the patient's stimulation parameters and contain a battery that provides energy.
Study NCT05419583 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Description: Ultrasound scan of the heart
Study NCT05419583 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac MRI scan
Description: An MRI scan to assess the heart structure and function
Study NCT05419583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Drug (Aspirin or Statin)
Description: Antiplatelet therapy for coronary artery disease
Study NCT05419583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin)
Description: Anticoagulant therapy if atrial fibrillation identified (DOAC or Warfarin)
Study NCT05419583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guideline directed heart failure therapy
Description: Use of guideline approved heart failure treatments (ACE-inhibitor / angiotensin receptor blocker (ARB) / ARB and neprilysin inhibitor, mineralocorticoid receptor antagonist, beta blocker, SGLT-2 inhibitor, diuretic therapy)
Study NCT05419583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins (Cardiovascular Agents)
Description: Statins will be recommended for patients with coronary plaque disease or hypercholesterolaemia
Study NCT06231381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB0034
Description: Anti-IL-36R antibody
Study NCT06231381 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-biologically active drug
Study NCT04744675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 40mg/mL
Description: Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intramuscular, intra-articular, and intrabursal injection.
Study NCT04744675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Saline is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium chloride and, in some formulations, potassium chloride and potassium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body.
Study NCT04744675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine is an anesthetic that is commonly used as a local numbing agent, including intramuscular, intra-articular and intrabursal injections.
Study NCT06048133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine IV: Day 1, 8, 22, and 29 every 42 days
Study NCT06048133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin IV: Day 1, 8, 22, and 29 every 42 days of Cycles 1-4 only.
Study NCT06048133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab IV: Day 1 and 22 every 42 days
Study NCT06048133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quemliclustat
Description: Quemliclustat IV: Day 1, 15, 29 every 42 days
Study NCT06114121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block (ESP)
Description: nerve block for abdominal pain. administered once immediately prior to spinal anesthetic standard of care.
Study NCT06114121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duramorph
Description: 100 micrograms (mcg) of morphine administered in the spinal medications one time.